Evidence map›Paper›PMID 42063134›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026

Prediction of relapsed/refractory primary central nervous system lymphoma using pre-chemotherapy ITSS grade on SWI and pre-/post-chemotherapy ADC parameters on DWI.

Yijing Zhao, Feiman Yang, Meina Li, Feifei Yu, Na Lin, Dairong Cao, Zhen Xing

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yijing Zhao *Department of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Feiman Yang *Department of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Meina LiDepartment of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Feifei YuDepartment of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Na LinDepartment of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Dairong CaoDepartment of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. dairongcao@163.com.
Zhen XingDepartment of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. anight306@126.com.

Funding

Fujian Provincial Health Technology Project No.2024CXA027the Joint Funds for the Innovation of Science and Technology, Fujian Province No.2025Y9219the National Natural Science Foundation of China No. 82371905
6 · The paper itself

Abstract

objectivesThe purpose of this study was to evaluate the role of SWI and DWI in predicting the relapsed/refractory primary central nervous system lymphoma (R/R PCNSL). MATERIALS AND

methodsSeventy-seven patients with histologically confirmed PCNSL were enrolled. Patients were divided into R/R group (n = 40) and Non-R/R group (n = 37), according to follow-up outcomes. Demographics, pathological indicators, conventional MRI characteristics, pre-chemotherapy intratumoral susceptibility signal (ITSS) grade, ADC parameters, including pre-chemotherapy relative minimum ADC (rADC

resultsCompared with Non-R/R PCNSL group, R/R PCNSL group showed significantly lower Ki-67 index (P = 0.004) but higher pre-chemotherapy ITSS grade (P < 0.001). The comparison of rADC

conclusionsThe pre-chemotherapy ITSS grade, rADC

Indexed as

Central Nervous System NeoplasmsDiffusion Magnetic Resonance ImagingLymphomaMagnetic Resonance ImagingNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesDiffusion weighted imagingPrimary central nervous system lymphomaRelapsed/refractorySusceptibility weighted imaging

Identifiers

PMID42063134
PMCPMC13281242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.